scholarly journals Early postpartum resting‐state functional connectivity for mothers receiving buprenorphine treatment for opioid use disorder: A pilot study

2019 ◽  
Vol 31 (9) ◽  
Author(s):  
James E. Swain ◽  
S. Shaun Ho
Keyword(s):  
Pilot Study ◽  
Functional Connectivity ◽  
Resting State ◽  
Opioid Use Disorder ◽  
Opioid Use ◽  
Resting State Functional Connectivity ◽  
Early Postpartum ◽  
Buprenorphine Treatment

Altered habenula resting state functional connectivity in deprived veteran tobacco smokers: A pilot study

2020 ◽  
Vol 84 (1) ◽  
pp. 21-34
Author(s):  
Cassandra Jennings ◽  
Savannah Gosnell ◽  
Kaylah N. Curtis ◽  
Thomas Kosten ◽  
Ramiro Salas
Keyword(s):  
Pilot Study ◽  
Functional Connectivity ◽  
Tobacco Smoking ◽  
Resting State ◽  
Nicotine Withdrawal ◽  
Frontal Pole ◽  
Resting State Functional Connectivity ◽  
Tobacco Withdrawal ◽  
Lingual Gyrus ◽  
The Right

This study aimed to examine habenular resting state functional connectivity (RSFC) abnormalities in tobacco-smoking veterans. The authors explored RSFC in sated smokers (n = 3D 18), overnight deprived smokers (n = 3D 13), and nonsmoker controls (n = 3D 26). Seed-to-voxel analysis was used to explore RSFC in the habenula. Compared to sated smokers, deprived smokers demonstrated higher RSFC between the right habenula and two clusters of voxels: one in the right fusiform gyrus, and one in the left lingual gyrus. To study nicotine withdrawal, the authors used the Shiffman-Jarvik Withdrawal Questionnaire (SJWQ) score as a regressor and found higher RSFC between the right habenula and the left frontal pole in deprived compared to sated smokers. Right habenula RSFC distinguished between sated and deprived smokers and differentiated between sated and deprived smokers when using SJWQ as a regressor, suggesting a habenular role in tobacco withdrawal.

Feasibility and Acceptability of reSET-O®: Patient and Provider Reported Experiences in a Pilot Study of a Novel Digital Therapeutic in People with Opioid Use Disorder (Preprint)

2021 ◽  
Author(s):  
Sarah Kawasaki ◽  
Sara Mills-Huffnagle ◽  
Nicole Aydinoglo ◽  
Halley Maxin ◽  
Edward Nunes
Keyword(s):  
Pilot Study ◽  
Cognitive Behavioral Therapy ◽  
Behavioral Treatment ◽  
Behavioral Therapy ◽  
Contingency Management ◽  
Opioid Use Disorder ◽  
Cognitive Behavioral ◽  
Opioid Use ◽  
Hub And Spoke ◽  
Buprenorphine Treatment

BACKGROUND Medications for treatment of opioid use disorder (OUD), such as buprenorphine, are effective and essential for addressing the opioid epidemic. However, high dropout rates from medication remain a challenge. Behavioral treatment with contingency management plus cognitive behavioral counseling has shown promise for improving outcomes of buprenorphine treatment, but is complicated to deliver. Delivery of behavioral treatment through technology-based platforms has the potential to make it more feasible for widespread dissemination. OBJECTIVE reSET-O® is a Prescription Digital Therapeutic and a commercial adaptation of the Therapeutic Education System, an internet-based, interactive program with a Community Reinforcement Approach to cognitive behavioral therapy. It delivers cognitive behavioral therapy modules and contingency management rewards upon completion of modules and negative urine drug screens. A pilot study was performed to assess feasibility and acceptability of reSET-O® in a Hub and Spoke model of care as part of a larger strategy to maintain individuals in treatment. Objective and qualitative results, as well as acceptability and likeability of reSET-O®, were obtained from fifteen individuals. METHODS English-speaking individuals over the age of 18 with a diagnosis of current OUD were recruited after being on buprenorphine for at least one week of treatment. Two 12-week prescriptions for reSET-O® were written for a 24-week study. Patient report of drug use and likeability scales of reSET-O® were conducted at weeks 4,8, 12 and 24 of the study. Qualitative interviews were also conducted. Four providers were recruited and gave feedback on the acceptability and feasibility of reSET-O®. RESULTS Of 15 participants who entered this pilot study, 7 completed 24 weeks and 8 were unable to complete due to drop out after enrollment, attrition in treatment, or incarceration. An average of $96 in contingency management rewards were earned by the participants for completion of modules for the duration of the pilot study. Participants’ subjective feedback found that reSET-O® was easy to use, enjoyable, and helped provide a safe space to admit recurring substance use. CONCLUSIONS ReSET-O® was well accepted based on patient and provider feedback in this pilot study, but adherence and retention in treatment remain areas for improvement, as with traditional MOUD and CBT approaches. A randomized control trial in a Hub and Spoke model will be needed to assess if retention on buprenorphine treatment is enhanced through the use of technology based behavioral interventions such as reSET-O®. CLINICALTRIAL NCT03826966

Sign in / Sign up

Export Citation Format

Share Document